What Could Send Pfizer Stock Soaring

Pfizer has demonstrated remarkable rallies, with its stock surging over 30% in under two months during key periods like 8232021 and 12152021. These swift upswings have rewarded investors with substantial gains. If similar catalysts emerge, Pfizer shares could be poised for another significant advance, building on its track record of rapid, powerful rallies.

Specifically, we see these catalysts:

1. Seagen Integration Unlocks Oncology Leadership
2. GLP-1 Entry into High-Growth Obesity Market
3. RSV Vaccine Market Share Acceleration

Catalyst 1: Seagen Integration Unlocks Oncology Leadership

• Details: Projected $10B+ risk-adjusted revenue contribution by 2030, Pathway to eight or more blockbuster cancer drugs by 2030, Doubling of early-stage oncology clinical pipeline,
• Segment Affected: Oncology
• Potential Timeline: Mid-2026 through 2030
• Evidence: Successful $43B acquisition of Seagen completed in late 2023, Management targeting biologics to be 65% of oncology revenues by 2030, up from 6% in 2023, Key ADC assets like Adcetris and Padcev adding billions in annual revenue,

Catalyst 2: GLP-1 Entry into High-Growth Obesity Market

• Details: Establishes foothold in projected $200B+ GLP-1 market by 2033, Diversifies revenue stream beyond oncology and vaccines,
• Segment Affected: Internal Medicine (Metabolic)
• Potential Timeline: Early 2026 for Phase II data, potential launch post-2027
• Evidence: Advancing once-daily oral GLP-1 candidate, danuglipron, Strategic acquisitions including Metsera for up to $10B and licensing deal with YaoPharma, Phase II obesity data expected in early 2026,

Catalyst 3: RSV Vaccine Market Share Acceleration

• Details: Capturing larger share of a rapidly growing multi-billion dollar market, Offsetting declining COVID-19 vaccine revenues,
• Segment Affected: Vaccines
• Potential Timeline: Q4 2025 – Q2 2026 Earnings
• Evidence: Abrysvo market share exceeding 50% of shipped volume in Q3 2024, Retail vaccination share climbing to 43% by mid-October 2024, RSV vaccine market projected to grow at a CAGR of over 40% from 2026 to 2033,

But The Stock Is Not Without Its Risks

Here are specific risks we see:

• Imminent Patent Cliff
• Deteriorating Shareholder Returns
• Oncology Portfolio Under Pressure

Looking at historical drawdown during market crises is another lens to look at risk.

PFE fell 39% in the Dot-Com bust, 53% in the Global Financial Crisis, and 54% during the Inflation Shock. Even smaller dips like 2018 and Covid hit around 24-29%. Risk is real.

Reference: Current Fundamentals

• Revenue Growth: 3.9% LTM and -13.2% last 3-year average.
• Cash Generation: Nearly 16.5% free cash flow margin and 24.6% operating margin LTM.
• Valuation: Pfizer stock trades at a P/E multiple of 14.6

*LTM: Last Twelve Months | If you want more details, read Buy or Sell PFE Stock.

Still not convinced about PFE stock? Consider Portfolio Approach

Move Beyond Single Stocks With A Multi Asset Portfolio

Individual picks are volatile but diversified assets offset each other. A multi asset portfolio helps you stay the course capture upside and reduce downside.

The asset allocation framework of Trefis’ Boston-based, wealth management partner yielded positive returns during the 2008-09 period when the S&P lost more than 40%. Our partner’ strategy now includes Trefis High Quality Portfolio, which has a track record of comfortably outperforming its benchmark that includes all 3 – the S&P 500, S&P mid-cap, and Russell 2000 indices